U.S. License Holder:
Genentech
Date of License:
June-29-2020
Last Update:
Nov-15-2024
FDA-Approved Indications
PHESGO (pertuzumab; trastuzumab; hyaluronidase-zzxf) is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for:
Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; or adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence;
Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
U.S. Patent Litigations